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Abstract: Besides their medical importance, the parasitic protozoan Trypanosoma brucei and its relatives are 
experimentally highly accessible model systems for many cell biological processes. Trypanosomes are phylo-
genetically essentially unrelated to the popular model eukaryotes, such as yeast and animals, and thus show 
several unique features, many of which are connected to RNA. Here we review the tRNA biology of trypano-
somes. Even though tRNAs were already discovered 60 years ago, owing to current technological advances 
in the field, research on tRNA biology has seen a Renaissance in recent years. First we discuss the extensive 
mitochondrial tRNA import process and the consequences it has for the parasite. Next we focus on trypanosomal 
aminoacyl-tRNA synthetases, some of which may be exploited as drug targets. Furthermore, we summarize what 
is known about trypanosomal tRNA modifications in both the cytosol and the mitochondrion. Finally, we provide 
an overview on the emerging field of tRNA-derived fragments and their possible function as translation regulators. 
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1. Introduction
The parasitic protozoan Trypanosoma brucei and many of its 
relatives are the causative agents of devastating diseases in both 
humans and animals.[1] However, in addition to their clinical im-
portance trypanosomes have also proven to be excellent model 
systems for eukaryotic cell biology. There are two main reasons 
for this: (i) they are phylogenetically only remotely related to 
essentially all popular eukaryotic model systems such as yeast, 
mammals and other animals[2] and (ii) they are an experimentally 
highly amenable system. Thus, molecular genetic methods such 
as gene replacement by homologous recombination, tight control 
of gene expression by the tetracycline repressor, inducible highly 
efficient RNAi, etc. are being used on a routine basis since many 
years.[3]
Decades of research with trypanosomes has led to a number 
of landmark discoveries that had impact on cell and molecular 
biology in general.[4] In the field of RNA biology, they include 
that RNA polymerase II transcription of protein coding genes is 
polycistronic, constitutive and strictly coupled to trans-splicing to 
an identical leader sequence.[5] Another example is RNA editing, 
the post-transcriptional change of an mRNA sequence, which was 
originally discovered in the mitochondrion of trypanosomatids. [6] 
Today we know that RNA editing is a ubiquitous process, al-
though its mechanisms vary in the different systems.[7] The aim 
of this review is to summarize another well studied but less known 
aspect of trypanosomal RNAs, namely the biology of its tRNAs. 
The T. brucei genome encodes 50 tRNA genes specifying 40 
different isoacceptors. Most trypanosomal tRNA genes are found 
in clusters of two to five tandemly repeated genes showing both 
sense and anti-sense orientations.[8] As in other eukaryotes, tRNA 
genes are transcribed by RNA polymerase III. The tRNATyr is the 
only one that requires splicing for its maturation.[9] Its 11 nucleo-
tide intron is removed by orthologues of the eukaryotic-type 
tRNA splicing system in the cytosol.[10] Unexpectedly, splicing of 
the tRNATyr depends on a single G to U and several G to A editing 
events within the intron.[11]
In summary, trypanosomal tRNAs look like bona fide eukary-
otic tRNAs, there is nothing unusual about them. However, if we 
look at their genetic origin, the situation looks different. Whereas 
tRNAs involved in mitochondrial translation are normally encod-
ed on the organellar genome, this is not the case in trypanosomes 
whose mitochondria completely lack tRNA genes.
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of tRNA is not affected by ablation of IF2 and therefore does 
not depend on cytosolic translation suggests a direct role of EF1a 
that is not related to translation. Since EF1a is a cytosolic protein 
that is not imported into mitochondria it could be that it brings 
the tRNA to the vicinity of mitochondria. Having said that, the 
requirement of EF1a is not absolute, since a tRNATyr variant, that 
is deficient in splicing and cannot be aminoacylated and therefore 
presumably does not interact with EF1a, nevertheless is imported, 
albeit less efficiently.[21]
Besides the import specificity an important question is, how 
the extent of import, which varies by a factor of ten or more be-
tween different tRNAs,[8c] is determined. Presently we do not have 
an answer to this question.
2.2 OM Proteins Required for tRNA Import
The tRNA import process starts in the cytosol by binding of 
tRNAs to EF1a which explains the specificity of the process. 
However, the most difficult to understand step is how tRNAs, high-
ly charged macromolecules of ca. 25 kDa mass, are translocated 
across the two mitochondrial membranes. Recently, some prog-
ress has been made regarding which proteins in the mitochondrial 
outer membrane (OM) are required for the process. This was pos-
sible because the OM proteome of T. brucei had been character-
ized.[22] It was therefore clear that whatever proteins are required 
for tRNA translocation across the OM, they must be among the 
82 proteins making up the OM proteome. It had previously been 
shown that the most abundant OM protein, the voltage depen-
dent anion channel (VDAC), unlike in the plant system,[23] is not 
required for tRNA import.[24] The same was the case for Sam50, 
the core subunit of the OM localized β-barrel protein insertase.[25] 
Next the subunits of the main trypanosomal protein translocase 
of the OM (TOM) were analyzed for their involvement in tRNA 
import. The trypanosomal TOM complex is unique in that only 
two of its seven subunits have orthologues in other eukaryotes.[26] 
It was therefore termed atypical TOM complex (ATOM).[27] Using 
inducible RNAi cell lines for individual ATOM subunits allowed 
to determine the effects the lack of each subunit has on protein 
and tRNA import, respectively. The results showed that while 
the ATOM core subunits (ATOM40, ATOM14, ATOM12 and 
ATOM11) were required for both protein and tRNA import, the 
two protein import receptors (ATOM46, ATOM69) were neces-
sary for protein import but dispensable for tRNA import.[28] Thus, 
in cell lines ablated for ATOM46, ATOM69 or for both receptors 
at the same time, tRNA import could be uncoupled from protein 
import. Further experiments showed that plugging the ATOM40 
import pore by a stuck precursor protein simultaneously inhibited 
protein and tRNA import.[28] These experiments show that both 
proteins and tRNAs use the β-barrel protein ATOM40 to translo-
cate across the OM. However, unlike suggested in yeast,[29] tRNAs 
are not co-imported with proteins, since tRNA import still works 
in cell lines that cannot import proteins due to depleted protein 
import receptors. All results described above were obtained by in 
vivo studies and thus are physiologically relevant. Moreover, great 
care was taken to detect potential unwanted indirect effects. Thus, 
the mitochondrial proteomes of uninduced and induced ATOM 
subunit RNAi cell lines were analyzed to determine whether other 
OM proteins than the RNAi targets were also downregulated.[28] 
In summary, these analyses corroborated that the inhibition of 
tRNA import seen in the RNAi cell lines is a direct consequence 
of the lack of the corresponding ATOM subunits.
2.3 IM Proteins Required for tRNA Import
How tRNAs are transported across the mitochondrial inner 
membrane is less clear. An in vivo study has shown that ablation 
of Tim17, a core subunit of the non-canonical trypanosomal inner 
membrane protein translocase, affects import of newly synthe-
sized tRNA and the same was the case for mitochondrial heat 
2. Mitochondrial tRNA Import (Fig. 1)
18 proteins are encoded on the mitochondrial genome of try-
panosomes and produced within the organelle. In order to com-
pensate for the lack of tRNA genes, trypanosomal mitochondria 
therefore must import all tRNAs from the cytosol in quantities 
sufficient to support mitochondrial translation.[12] Mitochondrial 
tRNA import is widespread but has experimentally been analyzed 
in few systems only.[13] The number of tRNAs postulated to be 
imported is highly variable. Whereas many systems lack some 
mitochondrial tRNA genes, they have retained at least a few tRNA 
genes in the mitochondrial genome. Thus, the complete lack of 
mitochondrial tRNA genes as seen in trypanosomes is unusual 
and makes trypanosomes an excellent system to study tRNA im-
port into mitochondria.
2.1 Specificity of tRNA Import
In trypanosomes, the set of mitochondrial tRNAs complete-
ly overlaps with the set that is found in the cytosol. Thus, there 
are single nuclear gene products which code for both cytosolic 
and mitochondrial tRNAs. In all cases, the major fraction of a 
given tRNA is found in the cytosol, where it functions in cyto-
solic translation, and only a small fraction – between 1 and 14% 
depending on the tRNA species – is imported into mitochondria, 
where it is used for mitochondrial protein synthesis.[8c,12] There 
are no nuclear genes coding for mitochondria-specific tRNAs, 
not in trypanosomes and also not in all other systems shown to 
import mitochondrial tRNAs. However, while all mitochondrial 
tRNAs from trypanosomes are imported from the cytosol, there 
are two cytosol-specific tRNAs: the initiator tRNAMet-i[14] and the 
tRNASec.[15] The eukaryotic-type initiator tRNAMet-i could not pos-
sibly function in the context of the bacterial-type mitochondrial 
translation system and selenocysteine insertion systems are not 
found in organelles, it therefore makes sense that these two tRNAs 
stay in the cytosol.
What determines the specificity of tRNA import? It has been 
shown that the genomic context from which the tRNA is expressed 
is not important for mitochondrial import.[16] Moreover, there is no 
feature specific for trypanosomal tRNAs that promotes their im-
port, because a yeast and a human tRNA were also imported when 
expressed in trypanosomes.[16,17] The targeting signal for tRNAs 
was identified by expressing chimeras between the cytosol-spe-
cific tRNAMet-i and the in part imported elongator tRNAMet-e, which 
differ by 26 nucleotides only.[18] The results showed that a switch 
of two adjacent base pairs in the T-stem of the elongator tRNAMet-e 
or initiator tRNAMet-i was sufficient to prevent or induce mitochon-
drial import of the corresponding tRNA variants. Interestingly, the 
two nucleotide pairs in the initiator tRNAMet-i overlapped with the 
antideterminants for eukaryotic elongator factor 1a (EF1a) bind-
ing as defined in other systems.[15] This suggests that for a tRNA 
to be imported into mitochondria, it needs to interact with EF1a. 
Indeed, as the tRNASec does not interact with EF1a but has its 
own elongation factor this also explains the exclusive cytosolic 
localization of the trypanosomal tRNASec. In line with this, a vari-
ant of the tRNASec in which the anti-determinant for EF1a bind-
ing (the eighth base pair in the acceptor stem) was mutated and 
binding of EF1a was induced resulted in mitochondrial import 
of the variant tRNASec.[15] The direct requirement for EF1a for 
mitochondrial tRNA import was finally demonstrated by the fact 
that its ablation, in contrast to ablation of initiation factor 2 (IF2), 
abolished mitochondrial tRNA, whereas the effects on transla-
tion were identical after ablation of either of the two translation 
factors.[15] Thus for a tRNA to be imported into mitochondria of 
trypanosomes it first needs to interact with EF1a in the cytosol. 
Since only aminoacylated tRNAs interact with EF1a, this strongly 
suggests that, unlike initially proposed,[19] tRNAs are imported as 
fully processed and aminoacylated molecules.[20] The precise role 
EF1a plays in tRNA import remains unclear. The fact that import 
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cess.[33] However, for the key publication implicating the F1a 
in tRNA import[32b] an editorial expression of concern has been 
published. [34] Moreover, it has been shown in two in vivo studies 
that F1a[25] and the Rieske protein[35] are not required for tRNA 
import in T. brucei. Thus, the Leishmania studies in question will 
not be further discussed here.
3. Aminoacyl-tRNA Formation
3.1 Dually Localized Aminoacyl-tRNA Synthetases
Non-plant eukaryotes in general contain a full cytosolic and 
a full mitochondrial set of aminoacyl-tRNA synthetases (aaRSs), 
although a few aaRSs might be dually targeted. Due to the lack of 
mitochondrial tRNA genes, the set of mitochondrial and cytosolic 
tRNAs are identical in trypanosomes with the exception of the 
cytosol-specific tRNAMet-i and the tRNASec (see above). It would 
therefore be expected that the same applies to the trypanosomal 
aaRSs. A survey of the T. brucei genome shows that this indeed 
shock protein 70 (mHsp70).[25] In both cases, inhibition of tRNA 
import was observed at a time point where the mitochondrial 
membrane potential was still intact. Moreover, in a different study 
mitochondrial membrane proteins were subjected to tRNA affinity 
purification, which recovered 44 proteins, including mHsp70. [30] 
Ablation of two trypanosomatid-specific proteins present in this 
list affected growth and inhibited import of newly synthesized 
tRNAs in vivo. When one of them was tagged and precipitated, 
it recovered many subunits of the trypanosomal TIM complex.[31] 
In summary, these results suggest that also in the case of the IM, 
tRNA import might require similar components to mitochondrial 
protein import. However, unlike for the ATOM subunits, the mi-
tochondrial proteome of none of the RNAi cell lines was globally 
analyzed, thus indirect effects, while unlikely, cannot be excluded.
tRNA translocation across the IM has also been studied in 
Leishmania tropica.[32] It was claimed in these studies that a 
complex of six essential proteins, including the alpha subunit of 
the F1 ATPase (F1a) and the Rieske protein, mediates the pro-
Fig. 1. Mitochondrial tRNA import 
and its connection to mitochondri-
al protein import in T. brucei. Left 
panel, mitochondrial tRNA import. 
Proteins experimentally shown 
to be essential for mitochondrial 
tRNA import are indicated in or-
ange. Proteins experimentally 
shown not to be involved in tRNA 
import are indicated with broken 
lines and light grey. Binding to 
EF1a is a prerequisite for tRNA im-
port and explains the specificity of 
the process. The cytosol-specific 
tRNAMet-i and tRNASec do not bind 
to EF1a but to initiation factor 2 
(IF2) or selenoscysteine specific 
elongation factor (EFsec). tRNA 
import uses the pore of ATOM40 
to translocate the OM but is 
independent of the two protein 
import receptors ATOM46 and 
ATOM69, indicating that tRNAs 
are not co-imported with proteins. 
Ablation of TbTim17 and mHsp70 
inhibits tRNA import, other TIM 
complex components have not 
been tested. Tb927.11.12740 and 
Tb927.9.7830 have also been 
implicated in tRNA import and 
appear to be associated with 
the TIM complex. Right panel, 
mitochondrial protein import. All 
orange proteins were shown to be 
essential for mitochondrial protein 
import. This includes the two pro-
tein import receptors ATOM46 and 
ATOM69 which are dispensable 
for tRNA import.
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mitochondrial LysRS of trypanosomes has not been elucidated. 
However, it was shown that in order to be active, the C-terminal 
extension of the imported version of the enzyme (LysRS2) has to 
be removed.[42]
3.3 Formation of Mitochondrial Formyl-Met-tRNAMet-e
All trypanosomal mitochondrial tRNAs are imported from the 
cytosol and therefore of the eukaryotic-type. However, they have 
to function in the context of the bacterial-type translation system 
of the mitochondrion. While for most tRNAs this is not prob-
lematic, the situation is different for the tRNAMet that functions 
in translation initiation, because this process works very differ-
ently in eukaryotic- and bacterial-type systems. In eukaryotes, it 
requires a dedicated initiator tRNAMet that has an A-T mismatch 
at the top of the acceptor stem, whereas in bacterial-type systems 
(including organelles) the initiator tRNAMet has a mismatch at the 
top of the acceptor stem.[46] Moreover, the bacterial-type tRNAMet-i 
not only needs to be aminoacylated by MetRS, but the methionine 
is further modified to formyl-methionine by a tRNA-dependent 
formyltransferase. Thus, translation in bacteria and organelles 
starts with formyl-methionine and only formylated tRNAMet-i is 
recognized by initiation factor 2 (IF2), the factor bringing the 
tRNA to the P-site of the ribosome.
In contrast to the cytosol-specific initiator tRNAMet-i, the cyto-
solic elongator tRNAMet-e is imported into mitochondria and it was 
shown that approximately 50% of it becomes formylated after 
import. The reaction is catalyzed by an unusual tRNAMet formyl 
transferase that has twice the mass of its orthologs in bacteria 
and eukaryotes and that selectively recognizes the imported 
tRNAMet-e.[14] As shown with in vitro experiments using mito-
chondrial extracts, it does not formylate the eukaryotic initia-
tor tRNAMet-i present in the cytosol. Thus, in T. brucei the single 
nucleus-encoded elongator tRNAMet-e has three different func-
tions in two compartments.[47] It mediates translation elongation 
in the cytosol and is required for both initiation and elongation 
in mitochondrial translation. Thus, it is the formyl-group that 
is recognized by mitochondrial IF2 and that allows to discrimi-
nate between elongator and initiator function of the imported 
tRNAMet-e.[48] Finally, as other systems, mitochondria of trypano-
somes contain peptide deformylases that remove the formyl group 
from the N-termini of at least newly synthesized proteins.[49]
3.4 Formation of Sec-tRNASec
Like all other tRNAs, eukaryotic tRNASec is transcribed by 
RNA polymerase III, although it requires extragenic promoter 
elements comparable to the U6 RNA. In trypanosomes, tRNASec 
genes are embedded within a large polycistron of protein-coding 
genes.[50] This is in contrast to all other tRNAs, which are clus-
tered in between polycistrons. It was shown that the T. brucei 
tRNASec in line with its genomic location, unlike any other tRNA, 
is transcribed by RNA polymerase II.[50] Consequently, it requires 
an external promoter for ectopic expression outside the polycis-
tron. A similar situation has been described for Leishmania.[51]
Unlike in bacteria, in which tRNASec is aminoacylated in two 
steps by the SerRS, creating Ser-tRNASec, which in turn is convert-
ed into Sec-tRNASec by the selenocysteine synthase,  eukaryotes 
and Archeae use a three-step pathway. Eukaryotic tRNASec first 
gets serylated by SerRS. However, unlike in bacteria, a phos-
phoseryl-tRNASec kinase (PSTK) phosphorylates the Ser on the 
tRNASec converting it into phospho-Ser-tRNASec. Finally, phospho-
Ser-tRNA:Sec-tRNA synthase (SepSecS) produces Sec-tRNASec 
as the final product.[52] Studies in T. brucei and its relatives have 
contributed to the characterization of the eukaryotic Sec-tRNASec 
formation pathway.[53] Using a combination of inducible RNAi and 
knockout cell lines allowed the first in vivo analysis of the com-
plete Sec-tRNASec formation pathway in a eukaryote. Moreover, 
the trypanosomal PSTK and SepSecS were able to complement 
is largely the case. It encodes for 23 different aaRSs, indicating 
that 17 aaRSs are encoded by single copy genes.[13d,36] Thus, we 
would expect that these 17 aaRSs function in both cytosolic and 
mitochondrial translation. Indeed, it has been experimentally veri-
fied for the cytosolic and mitochondrial GlnRS, GluRS[37] and 
TyrRS activities,[38] that each are encoded by a single nuclear 
gene. Typically, most of a given trypanosomal aaRS resides in 
the cytosol and only a minor fraction is imported. It can therefore 
be difficult to distinguish the small amount of aaRSs that is as-
sociated with the mitochondrion from cytosolic contamination. 
Recently, a new method termed importomics was introduced. It 
determined by SILAC proteomics the level of which mitochon-
drial proteins are reduced when import is abolished by ablation 
of the main OM protein translocase.[39] In this study, the levels 
of 16 mitochondria-associated, predicted to be dually targeted 
aaRSs (HisRS was not detected) were shown to be reduced in the 
absence of protein import, directly demonstrating that all trypano-
somal aaRSs are dually localized.
The mechanism that allows dual targeting of trypanosomal 
aaRSs has only been solved for the IleRS.[40] Differential trans-
splicing creates a long and a short variant of the enzyme. The pro-
tein product of the longer spliced variant has an amino-terminal 
presequence and therefore is found exclusively in mitochondria. 
Whereas the shorter spliced variant is translated to a cytosol-spe-
cific isoform that lacks the presequence.
3.2 Aminoacyl-tRNA Synthetases with Distinct 
Mitochondrial and Cytosolic Isoforms
While most trypanosomal aaRSs are dually localized, there 
are two distinct genes each for TrpRS,[41] LysRS[42] and AspRS,[43] 
which encode cytosol- and mitochondrion-specific enzymes, re-
spectively. This is surprising, since the cytosolic and mitochon-
drial substrate tRNAs for these aaRSs, as is the case for all other 
trypanosomal aaRSs, derive from the same nuclear gene.[36,44] 
The best understood cases are the two TrpRSs. They share 41% 
sequence identity, are both essential and of eukaryotic evolution-
ary origin. TrpRS1, the cytosolic version of the enzyme, amino- 
acylates cytosolic tRNATrp, but it cannot recognize the tRNATrp 
after it has been imported into mitochondria.[41] The reason for 
this is, that due to the reassignment of the stop codon UGA to 
Trp inside mitochondria, the C at wobble position of the tRNATrp 
gets edited to a U.[45] The edited mitochondrial tRNATrp can now 
decode both the UGG Trp-codon as well as the UGA codon, 
which in the cytosol function as a stop. In addition, the imported 
tRNATrp gets thiolated at the U at position 33. Both the edited 
U at the wobble position and the thiolated U33 act as antideter-
minants for charging by TrpRS1 as has been shown in vitro.[41] 
Thus, the re-assignment of the stop codon UGA to Trp in the 
mitochondrion requires two enzymes: i) an editing enzyme con-
verting the wobble C to an U, whose nature is still unknown,[45] 
and ii) a mitochondria-specific TrpRS, termed TrpRS2, that has 
an extended substrate specificity and therefore can aminoacylate 
both cytosolic and imported tRNAsTrp.[41]
While the existence of two trypanosomal TrpRSs can be 
linked to a mitochondrial genetic code variant, it is not known 
why trypanosomes have distinct cytosolic and mitochondrial 
AspRSs and LysRSs. The two AspRSs are of the eukaryotic-
type and 43% identical. Biochemical assays show the cytosolic 
enzyme, AspRS1, is specific for the cytosolic tRNAAsp and that 
it cannot aminoacylate the imported versions of the tRNAAsp. 
The mitochondrial enzyme, termed AspRS2, on the other hand 
can aminoacylate both cytosolic and imported tRNAAsp.[43] This 
strongly suggests that even though cytosolic and mitochondrial 
tRNAAsp derive from the same genes, they are physically different, 
most likely due to a mitochondria-specific nucleotide modifica-
tion of as yet unknown nature that is an antideterminant for the 
cytosolic AspRS1. The substrate specificity of the cytosolic and 
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for the absence of the Sec-tRNASec formation in an E. coli.[54] The 
analysis in trypanosomes was greatly facilitated by the fact that 
neither of the three selenoproteins encoded in its genome[53b] is 
essential for growth of the parasite.[54,55] Thus, in contrast to the 
transcription of the tRNASec gene, its aminoacylation pathway is 
highly conserved in all eukaryotes and Archaea. 
3.5 A Trypanosomal Multiple Aminoacyl-tRNA 
Synthetase Complex
In eukaryotes, cytosolic aaRSs are generally organized in a 
multiprotein assembly called the multiple aminoacyl-tRNA syn-
thetase (MARS) complex. In mammals, the MARS complex is 
composed of nine cytoplasmic aaRSs and three accessory pro-
teins. The organization of aaRSs in MARS complexes in eukary-
otes appears to improve the efficiency of tRNA-aminoacylation by 
tRNA channeling, which avoids tRNA diffusion in the cytoplasm 
and thus improves translation efficiency. Moreover, the MARS 
complex is also involved in translation regulation.[56] Recent work 
has shown that in T. brucei six cytoplasmic aaRSs together with 
three non-aaRSs proteins are also organized in a MARS complex 
in both bloodstream and insect stage forms.[44] Kinetic studies 
indicate that the trypanosomal MARS complex enhances the ef-
ficiency of tRNA-aminoacylation. Ablation of MCP2, one of the 
three non-aaRS proteins associated with the trypanosomal MARS 
complex, resulted in reduced growth of bloodstream form cells 
when grown in culture and in mice, respectively, indicating that 
the MARS complex might be a suitable target for drug develop-
ment.[44]
3.6 Trypanosomal Aminoacyl-tRNA Synthetases as 
Drug Targets
As might be expected from their biological function, all tested 
trypanosomal aaRSs were essential in both the insect stage and 
the disease-causing bloodstream form.[44,57] Thus, aaRSs might 
also be suitable drug targets to combat the diseases caused by 
T. brucei and its relatives. This has motivated a number of studies 
with the aim to identify inhibitors of trypanosomal aaRSs as lead 
substances for drug development: 
• A library of substances mimicking the lysyl adenylate com-
plex has been produced using solid phase combinatorial syn-
thesis and the resulting compounds were screened for inhibi-
tion of in vitro aminoacylation activity of T. brucei cytosolic 
LysRS (LysRS1). The screen identified three substances that 
inhibited LysRS1 in the low µM range.[58]
• The single trypanosomal MetRS shows more similarities to 
bacterial than to eukaryotic enzymes, suggesting it might be a 
good drug target.[44,59] A collection of aminoquinolone-based 
compounds, which are potent inhibitors of bacterial MetRSs, 
were synthesized and tested for inhibition of the MetRS and 
growth of bloodstream form of T. brucei. Some of the tested 
substances inhibited growth of T. brucei in the nM range, but 
did not interfere with growth of mammalian cells at high µM 
concentrations. The most potent compound delayed mortality 
in a murine model of trypanosomiasis.[59] In a different study, 
urea-based MetRS inhibitors were designed, synthesized and 
tested. This led to the discovery of low nM inhibitors with 
high selectivity towards the T. brucei enzyme when com-
pared to the human one. One of them also inhibited growth 
of the parasite at µM concentration and another compound 
was shown to cross the blood brain barrier in mice. However, 
only limited suppressive action was observed in a murine 
model of trypanosomiasis.[60] A high-throughput screen of the 
‘NIH Molecular Libraries Small Molecule Repository’ was 
also performed. It identified substances that inhibit trypano-
somal MetRS and growth of T. brucei. The most potent one 
was subjected to structure-guided optimization, resulting in 
novel MetRS inhibitors with good potency.[61] Interestingly, it 
appears that resistance against the MetRS inhibitors described 
above develops only relatively slowly when compared to com-
mon anti-trypanosomal drugs. Moreover, unlike what was 
observed for other drugs, the resistance that was eventually 
obtained was due to overexpression of the target enzyme. [62] 
In yet another study, a large chemical library of 364’131 small 
molecules was screened to find inhibitors of MetRS activi-
ty. A counterscreen for toxicity and inhibition of growth of 
bloodstream form T. brucei were also performed, resulting in 
the identification of a number of compounds with sub µM 
potency.[63] MetRS was also investigated as a drug target in 
the trypanosomatid Leishmania donovani. High-throughput 
screening identified a highly potent inhibitor of the leishman-
ial enzyme which bound to the methionine pocket of MetRS. 
However, the compound was not active in an animal model of 
leishmaniasis.[64]
• One study targeted the single trypanosomal IleRS. It showed 
that analogues of the Ile-AMP efficiently inhibited the en-
zyme. Moreover, the molecules were shown to selectively 
kill T. brucei in culture and one compound was able to cure 
trypanosome-infected mice. This makes Ile-AMP analogues 
promising leads for drug development, especially since some 
of them are known to cross the blood brain barrier.[65]
• Using benzoxaborole as the core, a collection of compounds 
was tested for inhibition of the single trypanosomal LeuRS. 
The substances were optimized to target the editing site of 
LeuRS using a structural homology model of the enzyme. This 
led to the discovery of inhibitors with an IC
50
 of less than 1.6 
µM that also inhibited growth of the parasites but not of mam-
malian cells.[66] In an extension of the study, docking-based 
virtual screening identified a new 2-pyrrolinone scaffold that 
inhibited the synthetic domain of trypanosomal LeuRS.[67]
• The activity of the single trypanosomal ThrRS, as well as 
growth of bloodstream trypanosomes, were inhibited by bor-
relidin, a natural product polyketide, in the nM and µM range, 
respectively.[57]
• Incubation of isolated, recombinant HisRS containing a bound 
histidine of Trypanosoma cruzi with 68 different cocktails from 
the medical ‘Structural Genomics of Pathogenic Protozoa’ 
fragment library identified 15 fragments that inhibited HisRS 
activity. Subsequently, their anticipated binding mode was 
confirmed crystallographically.[68] These substances may form 
the basis for the development of highly selective HisRS inhibi-
tors in the future.
4. tRNA Modifications
4.1 tRNA Molecules are Densely Decorated by 
Nucleoside Modifications 
All nucleic acids in a cell are subjected to chemical modifi-
cations as a post-replicative or post-transcriptional process. The 
biogenesis of these chemical modifications is driven by a vast 
number of highly specific enzymes capable of introducing diverse 
chemical functional groups on their nucleic acid substrates. RNA 
modification enzymes harbor a broad reaction repertoire including 
deaminations, isomerizations, glycosylations, thiolation, transgly-
cosylation or methylations (reviewed in ref. [69]). Even more com-
plex modifications are possible, in which sugars or amino acids are 
attached to the nucleobase base or ribose, respectively. While DNA 
modification is dominated by methylations, the chemical reper-
toire of post-transcriptional RNA alterations is significantly more 
diverse. Until today, about 150 unique RNA modifications have 
been characterized across all three domains of life.[70]
tRNA molecules are the most frequently targeted class for 
nucleic acids modifications and carry, on average, 13 modifica-
tions per molecule.[71] On average 17% of residues are post-tran-
scriptionally altered, which is almost ten times more compared 
400 CHIMIA 2019, 73, No. 5 NCCR RNA & DiseAse
ed by the fact that almost every tRNA is modified at position 34 
(the wobble nucleotide) and position 37 (the nucleotide flanking 
the anticodon). Modifications at position 37 prevent frameshifting 
and help to stabilize the anticodon-codon interaction during trans-
lation in the A site of the ribosome (reviewed in ref. [69]). Recent 
ribosome profiling evidence suggests that the 5-methoxycarbon-
ylmethyl-2-thiouridine modification at the wobble position also 
affects the speed of translation and thus modulates protein folding 
and proteostasis in Mammalia.[80] In some cases, the tRNA modi-
fication status can be highly dynamic and therefore serves a regu-
latory function. For example, chemical and temperature stress 
have been shown to influence modification levels at the wobble 
position,[81] thus potentially adjusting the cellular translatome 
during environmental challenges. In yeast it was demonstrated 
that during oxidative stress, an increase of the m5C modification 
at the wobble position of tRNALeu(CAA) promotes the selective 
translation of mRNAs enriched for TTG codons. By this adaptive 
mechanism, proteins involved in the resilience towards oxidative 
stress get preferentially expressed.[81a] Additionally, tRNA modi-
fications in pathogenic fungal and bacterial pathogens have been 
linked to modulate stress responses during infection.[82] For try-
panosomatids, however, the role of dynamic tRNA modification 
during stress and infection remains to be elucidated.
Recently tRNA modifications at positions 34 and 37 have been 
put into context of a structure- and energy-based view of the ge-
netic code.[83] In this scenario, modifications at these two posi-
tions are especially crucial for stabilizing the thermodynamically 
weak AU-rich codon-anticodon pairs in the ribosomal A-site. This 
allows a uniform, balanced and accurate decoding at the ribosome 
despite the quite large differences in binding energies between 
strong (GC-rich) and weak (AU-rich) codons-anticodon duplexes. 
The third class (III) of tRNA modifications involves those 
that affect ‘non-canonical’ functions of tRNA molecules. ‘Non-
canonical’ is meant here in the sense of fulfilling biological roles 
that go beyond directly serving as substrates for protein biosyn-
thesis.[74] It has been shown that certain modifications influence 
tRNA cleavage efficiency into smaller fragments and some even 
play a direct role in the biological function of tRNA fragments 
(see section 5.4). 
4.3 tRNA Modifications in Trypanosomatids
Trypanosomatids are appreciated as divergent eukaryotes with 
a remarkable and unique RNA biology such as extensive mRNA 
editing in mitochondria (see Introduction). RNA editing is how-
ever not limited to mRNAs but was also described to occur on 
tRNA molecules (reviewed in ref. [84]). In trypanosomatids, two 
tRNA editing events were previously described, namely formation 
of inosine by deamination of adenosine (A to I editing) and cyti-
dine deamination to yield uridine (C to U editing) in the anticodon 
loop.[45,85] Inosine at the first position of the anticodon allows the 
recognition of three different nucleotides at the third mRNA codon 
position (A, C, or U) and thus expands the decoding capacity of 
a tRNA.[86] Like in mammals, also trypanosomatids possess eight 
tRNAs with a genetically encoded adenosine at the wobble base 
(position 34) in the anticodon loop.[87] To enable the decoding of 
not only U-ending codons but also C-ending codons, this adenos-
ine needs to be converted to an inosine for the expansion of the de-
coding capacity. A to I editing is crucial for viability in eukaryotes, 
since they lack tRNAs carrying a guanosine at the wobble position 
and therefore would not be able to decode C-ending codons in the 
absence of such an editing event. Additionally, the A to I tRNA 
editing events at position 34 are important determinants for their 
respective aminoacyl tRNA synthetases.[88] A to I editing is cata-
lyzed by enzymes called Adenosine Deaminases Acting on tRNAs 
(ADATs). In trypanosomatids, they function as a heterodimer of 
two subunits, ADAT2 and ADAT3, and are very much alike cyti-
dine deaminases.[89] A to I editing is not restricted to position 34 on 
to rRNA modifications (average 1–2% of residues are modified) 
(reviewed in ref. [69]). Nonetheless, there is a considerable quan-
titative variety of tRNA modifications between different organ-
isms and even within similar tRNA isoacceptors. In general, 
modifications of tRNAs increase in abundance from bacterial and 
organellar to eukaryotic tRNAs. Not only does the density of post-
transcriptionally altered residues vary but also the composition 
of modifications. Some of the chemical tRNA modifications are 
common at specific positions and show deep evolutionary conser-
vation in all three domains. Other modifications are highly specif-
ic to a particular organism or even to a specific tRNA isoacceptor. 
A common set of 18 modifications in tRNAs are universally con-
served and typically involve rather simple chemical alterations, 
such as the addition of a methyl group (reviewed in ref. [69]). Less 
conserved chemical modifications tend to be more complex in 
chemical composition and involve intricate biogenesis pathways. 
These more complex alterations, also called hypermodifications, 
are generally located in the anticodon loop of tRNAs (reviewed 
in ref. [72]). Experimental identification, mapping and functional 
characterization of RNA modifications have been challenging. 
However, new technical developments in mass spectrometry to-
gether with biophysical, biochemical and new genetic approaches 
led to a significant progress studying post-transcriptional modi-
fications recently. Nevertheless, it still remains a challenging en-
deavor to uncover the functional relevance of a particular tRNA 
modification since they are often functionally interdependent on 
a network of neighboring nucleoside modifications. 
4.2 Functions of tRNA Modifications
While it is often difficult to pinpoint the cellular role of an in-
dividual tRNA modification, global hypomodification was shown 
to correlate with decreased efficiency of protein biosynthesis, re-
sulting in imbalances in proteostasis and thus contributing to sev-
eral human diseases (reviewed in ref. [73]). Biological functions 
of tRNA modifications can be broadly grouped into three classes: 
those important for promoting and stabilizing the overall archi-
tecture of the tRNA structure (class I), those affecting mRNA de-
coding and translation efficiency (class II) and those influencing 
non-canonical tRNA functions (class III).[74] These non-canonical 
roles include tRNA fragment biogenesis, tRNA fragment function 
or serving as signaling molecules in bacterial stringent response 
or mammalian apoptosis regulation. 
Effects of tRNA modifications on the three-dimensional 
L-shaped structure of tRNAs (class I) were shown to be very 
subtle. The overall tRNA structure was shown to fold correctly ir-
respective of the modification status of tRNAPhe, including a fully 
formed anticodon stem-loop in E.coli.[75] However, minor varia-
tions became apparent in the angle between the anticodon stem-
loop and the acceptor stem, which seemed to be correlated with the 
modification status.[75] In other examples, the influence of a par-
ticular tRNA modification on the three-dimensional architecture 
is more pronounced, as in the case of the highly conserved m1A58, 
m1A9 or m5C38.[74,76] In all these cases, it seems that lack of these 
crucial methylations results in less compact tRNA folding, which 
renders these molecules prone to degradation by endonucleases. 
In general, modifications involved in adjusting subtle structural 
features are capable of either rigidifying the tRNA architecture or 
making it more flexible.[77] Both types of modification effects are 
essential for fine tuning tRNA stability, especially in response to 
environmental challenges. As an example, psychrophilic archaea 
harbor more flexibility-promoting modifications compared to 
thermophilic archaea.[78] Furthermore, the modification level of 
tRNAs were observed to change with increasing temperature and 
therefore maintaining a balance between stability and flexibility 
of the tRNA molecule depending on the temperature.[79] 
The modifications belonging to class II are essential for trans-
lation fidelity. The importance of these modifications is highlight-
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base, however, Suzuki and co-workers could identify a cytoplasm-
specific 2-thiouridine modification and a unique mitochondria- 
associated 1'-O-methyl uridine modification.[95] Posttranscriptional 
alterations at position 37 with the very complex chemical modi- 
fication wyosine (imG), wybutosine (yW) and hydroxywybuto-
sine (OHyW) were thought to serve as discriminators of eukaryal/
archaeal from bacterial tRNAPhe (GAA). However, recently wyo-
sine and its derivatives were found in mitochondria of trypanoso-
matids.[96] This was unexpected since it was generally assumed 
that mitochondrial tRNA modifications would resemble more 
the bacterial pattern due to their close evolutionary relationship. 
Probably these complex wyosine derivatives at position 37 are 
beneficial for maintaining the reading frame in mitochondrial 
translation in the light of the U-rich nature of mRNA codons in 
trypanosomal mitochondria that result from the immense U inser-
tion mRNA editing mechanism.
5. The Emerging Biology of tRNA-derived Fragments
5.1 tRNA Cleavage is Abundant and Conserved
Over the last six decades tRNAs have been primarily de-
scribed and viewed as universally conserved components of the 
translation machinery delivering activated amino acids to the 
ribosome and thus connecting the genetic triplet code with the 
amino acid sequence of proteins. A substantial change in our un-
derstanding of the complexity of tRNA biology emerged with the 
recognition that RNA molecules (coding and non-protein-coding) 
with well-identified cellular functions can act as precursors for 
post-transcriptional fragmentation, generating a further novel 
class of functional RNA species.[97] First evidence for abundant 
tRNA fragments was reported in human tumor tissues in 1977.[98] 
Subsequently, tRNA-derived cleavage products were described 
in Escherichia coli in response to T4 virus infection by the en-
donuclease PrrC.[99] This PrrC endonuclease cleaves tRNAs in 
their anticodon loop and therefore depletes the pool of mature 
tRNAs. As a consequence, the infected cell reduces translation 
of T4 proteins and therefore hampers virus proliferation. At that 
time, these cleavage entities were considered to be non-functional 
tRNA degradation products. This view changed during the last 
years due to the combination of high-throughput sequencing 
techniques and dedicated functional analyses. Recently, the field 
has witnessed the discovery of an unexpected functional diversity 
of tRNA-derived RNA fragments (typically abbreviated tRFs or 
tdRs) across all kingdoms of life. Today, tdRs are recognized as a 
rapidly expanding class of regulatory ncRNAs involved in various 
cellular functions with crucial roles in health and disease.[74,100]
5.2 Structural and Functional Heterogeneity of tRNA-
derived RNA 
Contrary to other classes of small regulatory ncRNAs, such as 
mi/siRNAs, tdR biogenesis and function is remarkably heteroge-
neous in various aspects. Firstly, tRNA cleavage occurs at different 
positions and involves distinct tRNA isoacceptors. Fragmentation 
generates tdRs of various sizes ranging from tRNA halves (size 
30–35 nt) to smaller tRNA fragments (~14–26 nt) deriving from 
both the 5' or 3' termini of the full-length tRNA molecule. The 
intracellular stability of the two produced tdRs can be signifi-
cantly different and can even change within the same organism. 
Additionally, tdRs can be generated from either the pre-tRNA or 
from the fully processed mature tRNA containing the post-tran-
scriptionally added 3' CCA-tail in eukaryotes. Moreover, tdRs 
have been described to originate from trimmed mature tRNAs 
without containing the 3' CCA-tail.[101] Not only can the 3' termini 
differ but also the chemical nature of the 5' termini and thereby 
further increase the diversity of tdRs.[102] The vast amount of cleav-
ing options within a tRNA molecule highlights only one aspect of 
the tdR heterogeneity. Secondly, another layer of tdR complexity is 
tRNAs but can also occur at position 37 neighboring the anticodon. 
Deamination at this position affects anticodon loop structure and is 
catalyzed by ADAT1.[89,90] C to U tRNA editing is less widespread 
in biology and has so far been described in trypanosomatids, mar-
supials, plants and archaea. [45,85b,91] tRNAs of trypanosomatids 
contain both C to U and A to I editing in one tRNA molecule simul-
taneously. Rubio and colleagues demonstrated the intertwinement 
of both editing reactions and the catalysis of both reactions by the 
same enzyme, namely the ADAT2/3 on the tRNAThr (AGU). C to U 
formation at position 32 was shown to promote further conversion 
of A to I at the wobble position 34 in cytosolic tRNAs.[85b] More 
recently, an even deeper layer of complexity was uncovered by the 
involvement of a post-transcriptional cytosine methylation event at 
position 32 as a prerequisite for subsequent deamination to uracil. 
Prior to the C to U deamination reaction at this site in T. brucei 
tRNAThr, the cytosine nucleobase is methylated to 3-methylcyto-
sine (m3C) by the methyltransferase TRM140. Once this modi-
fication is present, m3C is finally deaminated to 3-methyluridine 
(m3U).[85a]
Another example of C to U editing in the anticodon loop 
of a tRNA is well described in Leishmania tarentolae and in T. 
brucei.[41,45] These C to U editing events solve the inability of 
nuclear encoded tRNAs to decode the codons from the degenerate 
mitochondrial genetic code inside the mitochondria of trypano-
somatids. A very prominent example of codon reassignment is 
that of tryptophan codons. 88% of the tryptophan codons from 
the mitochondrial derived mRNA transcripts are encoded as 
UGA, which in cytoplasmic mRNAs typically represents one of 
the three canonical stop codons. However, the nucleus-encoded 
tRNATrp contains a CCA anticodon that can successfully decode 
UGG sense codons but not UGA stop codons. The uniquely mito-
chondrial localized C to U editing of the first anticodon position 
to generate tRNATrp (UCA) solves the mitochondrial decoding 
conundrum. [45] Additionally, tRNATrp encounters extensive mito-
chondria-specific post-transcriptional modifications. One such 
example is the mito chondrial thiolation of U
33
 (s2U
33
) of tRNATrp 
prior to C to U editing.[92] In Leishmania thiolation and editing 
levels were comparable (~50%) and due to the special proxim-
ity of these two events, it was hypothesized that U
33
 thiolation 
is required for C34 editing. However, it turned out in T. brucei 
that even though equivalent editing levels were detected as in 
Leishmania, 85% of tRNATrp was thiolated. This demonstrates 
that in either case edited and unedited tRNAs were subject to U
33
 
thiolation.[41] RNAi against the thiolation machinery in T. brucei 
increased the editing levels to almost 100%.[93] This data suggests 
that thiolation at position 33 acts as negative determinant for the 
C to U editing at the wobble position 34, which helps to maintain 
the ratios of edited and unedited tRNAs in T. brucei. However, 
this phenomenon is not commonly found in all trypanosomatids, 
since in Leishmania only the edited tRNATrp is thiolated.[93] These 
findings of tRNATrp highlight three important features of tRNA 
editing and tRNA modification in the context of the mitochondria. 
First, editing is essential to increase the decoding capacity in the 
mitochondria, second, editing is driven by the unique organellar 
localization of the editing enzyme and the specificity to tRNATrp 
and third, post-transcriptional modifications can have an impor-
tant function in the modulation of tRNA editing. 
Beside thiolation of U
33
, additional tRNA modifications have 
been described in trypanosomatids, which are specific for dis-
tinct cellular compartments. tRNALys (CUU), tRNALeu (CAA) and 
tRNATyr (GUA), which are all encoded in the nuclear genome of T. 
brucei, were shown to possess a distinct modification pattern de-
pending on their cellular localization in the cytosol or in the mito-
chondria.[94] Similarly, mitochondria-specific and cytosol-specific 
modifications were detected in Leishmania tarentolae in the anti-
codon loop of tRNAGlu (UUC). tRNAGlu in both compartments are 
decorated with a common mcmU34 modification at the wobble 
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majority of tdRs belonged to tRNA halves and derived from the 
5' part. The abundance of tRNA halves varied during different en-
vironmental stimuli and was specific to unique tRNA isoaccep-
tors.[101a] Hence, tRNA cleavage into halves results upon various 
growth and stress conditions and is tRNA species-dependent. Not 
only were tdRs identified as a part of the non-coding cellular tran-
scriptome but also in their respective secretomes in Trypanosoma 
cruzi, Leishmania donovani and Leishmania braziliensis.[104a,b] 
These protozoan parasites were shown to release RNA-containing 
extracellular vesicles that also include tdRs. The secretome study 
of both Leishmania species revealed a distinct population of tdRs 
compared to the intracellular tdRs population.[104b]
5.4 Biogenesis of tRNA-derived RNAs in Trypanosoma
As previously mentioned, the biological functions of tdRs are 
highly diverse. However, also the biogenesis pathways of the tdRs 
observed across different organisms are very heterogeneous. In 
yeast, Rny1, a member of the RNase T2 family, is responsible 
for the production of oxidative stress induced tRNA cleavage in 
the anticodon loop to generate tRNA halves.[112] In mammalian 
cells, stress-induced tRNA halves are generated by angiogenin, an 
RNase A-type enzyme.[105b] Trypanosomatids lack an angiogenin 
or an Rny1 homolog, implying an alternative biogenesis pathway. 
In plants and humans, it has been proposed that tdRs can also be 
produced by Dicer, a central endonuclease of the si/miRNA ma-
chinery.[113] Since a few members of the trypanosomatid family 
partially or totally lost the RNAi pathway, the Dicer homologs 
still present might be involved in the non-canonical tdRs bio-
genesis. However, RNAi experiments against the two Dicer-like 
proteins (TbDCL1 and TbDCL2) did not affect tRNA fragmenta-
tion in the anticodon loop of T. brucei.[101a] It seems that the tdR 
biogenesis in trypanosomes is unique and awaits identification of 
the involved nucleases.
In light of the discovery that tRNA fragmentation increases 
upon stress exposure, another pending question to be addressed 
concerns the role of post-transcriptional nucleoside modifications 
on tRNA molecules for tdR biogenesis. In Drosophila and hu-
man cells, it has been shown that indeed the presence of particular 
tRNA modification affects the production of tdRs.[114] The DNA 
methyltransferase Dnmt2 methylates three tRNAs in the anticodon 
loop in flies. Drosophila Dnmt2 mutants were less viable under 
stress conditions and the three unmodified tRNAs were more sus-
ceptible to cleavage by angiogenin. Schaefer and colleagues dem-
onstrated that stress-induced tRNA cleavage was indeed Dnmt2-
dependent, whereas the Dnmt2-mediated methylation protected 
tRNAs against stress-induced RNase cleavage.[114] Another hint 
that modifications influence tdR biogenesis comes from an exam-
ple in human disease.[115] The lack of tRNA methylation positively 
affected the production of tdRs and reduced protein translation 
rates. This effect contributed to human neurological disorders via 
stress-induced tRNA fragmentation.[115] It is therefore conceiv-
able that some tRNA modifications are not necessarily required 
for canonical tRNA function (class III modifications; see 5.2.), 
but might be crucial for tdR biogenesis and/or tdR functionality 
(reviewed in ref. [74]). Indeed, a recent study demonstrated that 
a particular tdR in human stem cells can only fulfil its biological 
role in case it carries pseudouridines.[116] Such a requirement for 
post-transciptional modification for tdR function, however, cannot 
be generalized. The tRNAThr 3' half shown to stimulate T. brucei 
translation neither depends on modifications for its biogenesis, nor 
for its regulatory function on the ribosome.[101a]
5.5 Function of tRNA-derived RNA in Trypanosoma 
The biological function of most of the identified tdRs in try-
panosomatids remained largely ambiguous up to date. Owing to 
the extreme functional heterogeneity of tdRs (see section 5.2), 
the mere identification of a tRNA-derived sequence in RNomes 
achieved by the alternative expression levels even within the same 
organism. tdR abundance can vary enormously in different tissues 
of an organism, during development and can heavily depend on 
environmental stimuli. Initially the phenomenon of tRNA cleavage 
has been described in the context of stress response. This stress-
induced tdR production is widespread and has been observed in ar-
chaea,[103] bacteria,[99] uni-[101,104] and multicellular eukaryotes.[105] 
However, more recent studies have demonstrated that tdRs can al-
so be constitutively present,[101a,106] thus highlighting the potential 
also for housekeeping roles. Thirdly, not only are tdRs highly het-
erogeneous in their structure and expression profiles but they also 
vary significantly in their cellular roles. tdRs have been reported 
to be involved in a plethora of biological functions including the 
regulation of transcription, translation, stress granule formation, 
apoptosis, cell proliferation, RNAi, vesicle-mediated intercellular 
communication, intergenerational inheritance, retrotransposons 
mobility (reviewed in ref. [100a]) and ribosome biogenesis.[107]
5.3 tRNA-derived RNAs in Trypanosomatids 
Lately, tdRs have also been characterized and their biology 
studied more extensively in trypanosomatids. During their com-
plex life cycles these parasites have to adapt to different environ-
mental challenges such as temperature shock, nutritional stress, 
oxidative stress and pH shift (reviewed in ref. [108]). These chang-
es are concerted with the rearrangement of gene expression. Since 
transcription regulation is essentially absent in trypanosomes, they 
are crucially dependent on post-transcriptional regulation mecha-
nisms to modulate gene expression.[109] Whereas well-character-
ized post-transcriptional mechanisms of gene regulation such as 
the RNA interference (RNAi) pathways are involved in most eu-
karyotes, the protozoan parasites Trypanosoma cruzi, Leishmania 
major, Leishmania donovani and Plasmodium falciparum are de-
ficient in the RNAi pathway (reviewed in ref. [110]). In contrast, 
Trypanosoma brucei possesses an endogenous siRNAs-guided 
RNAi pathway, however, the miRNA-guided translation regula-
tion seems to be absent.[111] Therefore, tdRs might represent a 
means for post-transcriptional regulation in the absence of tran-
scriptional control along with the lack of a complete RNAi path-
way in most of the trypanosomatids. Indeed, tdRs were identified 
in several trypanosomatids under different life stages and stress 
conditions.[101a,104a,b,106] The presence of tdRs in trypanosomatids 
was first reported in unstressed and nutritionally stressed T. cruzi 
cells by Garcia-Silva and colleagues.[104a] The authors constructed 
a 20-35 nt cDNA library and sequenced 348 clones. 26% of these 
clones were derived from tRNA and 60% from ribosomal RNA. 
Predominantly the tdRs derived from the 5' half of tRNAs and 
over 90% of tdRs originated from only three tRNA isoacceptors 
(tRNAAsp(GUC), tRNAGlu(CUC) and tRNAGlu(UUC)). Additionally, the 
nutritional stress condition stimulated tRNA cleavage. This im-
plies that tRNA cleavage is accentuated under nutritional stress in 
T. cruzi and 5' tRNA halves are generated from a constricted pool 
of tRNA isoacceptors. Later on, another independent cDNA li-
brary in T. cruzi was analyzed by Franzen et al.[106] In this study 
73% of the tdRs reads derived from the 3' halves including the 
post-transcriptionally added CCA-tail. These two transcriptome 
studies in T. cruzi illustrate the asymmetric stability of cleaved 
tRNAs within the same organism, depending on the stress condi-
tion and its life stage. Franzen and colleagues detected the major-
ity of tRNA halves deriving from the 3' end of mature tRNAs of 
epimastigote cells, with a preference for tRNAHis. However, upon 
nutritional stress, 98% of identified tRNA halves derived from the 
5' termini, mainly from tRNAGlu and tRNAAsp.[104a] This tdR state 
changed markedly in the metacyclic life stage, when 3' tRNA halves 
dominated with yet again a different preference for tRNA species.
[104a] A similar picture became evident by deep-sequencing of a 
cDNA library prepared from ribosome-associated small ncRNAs 
under various stress and life stage conditions in T. brucei.[101a] The 
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subsequently engulfed by mammalian cells and other parasites 
and stored in reservosomes. This data uncovers yet another layer 
of biological relevance of tdRs in trypanosomatids. In particular, 
tdRs can be involved in cell-to-cell communication between para-
sites or even a cross-kingdom transfer to mammalian cells. These 
vesicles were secreted by nutritionally stressed T. cruzi parasites 
and induced epigenetic changes in the susceptible mammalian 
cells. During early stage of invasion, gene expression changes 
were observed in murine cardiomyocytes, favoring the infection 
process from T. cruzi in mammalian cells. Incubation with the 
extracellular vesicles fraction of nutritionally stressed T. cruzi 
induced remodeling of the cytoskeleton and the extracellular ma-
trix, along with the expression of proinflammatory cytokines and 
other genes involved in the immune response.[118]
These new insights into tdRs in trypanosomatids cover a 
broad range of cellular function and add to the multifaceted reg-
ulatory potential of tdRs across all domains of life. Up to date, 
the biological relevance of many more identified tdRs awaits to 
be uncovered in the family of trypanosomatids. This might help 
to understand the peculiar RNA biology of trypanosomatids, es-
pecially for uncovering the hidden layer of post-transcriptional 
gene regulation. 
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impedes direct conclusions to be made about its biological sig-
nificance. As a consequence, dedicated experiments for basi-
cally every individual tdR are required for unraveling its biologi-
cal relevance. In trypanosomatids, this was achieved for only a 
handful of tdRs. The so far characterized tdRs are involved in di-
verse functions such as translation regulation,[101a] RNA interfer-
ence,[117] intercellular communication[118] and intergenerational 
inheritance. [118] A very recent publication in T. brucei revealed 
a novel layer of post-transcriptional regulation during stress re-
covery, driven by a ribosome-associated tRNA half.[101a] A deep-
sequencing approach revealed a 3' derived tRNAThr half, which 
accumulates upon nutritional stress in the procyclic form of 
T. brucei. This respective tRNA half associates with ribosomes 
and polysomes and was shown to globally stimulate translation 
during stress recovery by facilitating mRNA loading during 
translation initiation. The tRNAThr 3' half is the latest addition 
to an emerging class of ribosome-associated small ncRNAs 
(rancRNAs) present in all three domains of life.[119] RancRNAs 
were demonstrated to associate directly with the translation ma-
chinery and have the potential for acting as first wave stress 
regulators.[120] The tRNAThr 3' half is not the first tdR known 
to stimulate protein synthesis. In 2017, Kim and colleagues re-
ported on a 22 residue long tdR capable of fostering transla-
tion of at two ribosomal protein mRNAs and in the end fine-
tune the number of ribosomes in mammalian cells.[107] While 
tdR-mediated translation stimulation has been described only 
very recently, global inhibition of protein synthesis involving 
tdRs was first reported already in 2009.[121] Two stress-induced 
tRNA 5' halves (5' tRNAAla and a 5' tRNACys) were shown to 
inhibit translation and promote stress granule formation. From 
a mechanistic point of view, these tdRs were shown to contain a 
specific 4-G-quadruplex structure[122] and were able to interfere 
with the eIF4F initiation complex and therefore reduce trans-
lation initiation.[105b] Additionally, stress granule assembly was 
induced by direct association with the effector protein YB-1.[123] 
The formation of stress granules upon a global translation arrest 
is a general feature for eukaryotic cells and does not exclude try-
panosomatids. For example, stress granules were observed upon 
heat-shock, which leads to decreased polysome and mRNA lev-
els in T. cruzi.[124] However, stress granule formation was not 
affected by the recently described T. brucei tRNAThr 3' half.[101a]
Another function of tdRs, namely the involvement in the RNA 
interference pathway, was described in plants, fungi and animals. 
Various publications revealed that tdRs can directly participate 
as guide RNAs in the RNAi machinery. Some unicellular proto-
zoan belonging to the family of trypanosomatids, such as T. cruzi, 
L. major and L. donovani, lack or possess an extensively simpli-
fied machinery involved in the RNA interference pathway (re-
viewed in ref. [110]). This raises the question whether tdRs might 
be involved in an alternative small RNA-mediated pathway to 
regulate gene expression post-transcriptionally. Garcia-Silva and 
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in T. cruzi.[117] However, despite the demonstration of an inter-
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tional evidence for the involvement of tRNA fragments in RNAi 
is largely absent. The tdR-argonaute complexes were shown to 
be recruited to specific cytoplasmic granules, with a local dis-
tinction between 5'- and 3'-derived tRNA half complexes inside 
the cellular body.[117] Later on, these granules were identified as 
nutritional storage organelles, so-called reservosomes. These res-
ervosomes store nutrients that derive from the extracellular media 
by a vesicle mediated engulfment process in T. cruzi.[118] Garcia-
Silva and colleagues demonstrated the shedding event of vesicles 
containing tdRs and the argonaute protein TcPIWI-tryp as cargo 
during nutritional stress.[118] These tdRs-containing vesicles were 
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